Changing the basic treatment as a way to achieve asthma control
- Authors: Kurbacheva OM1, Pavlova KS1
-
Affiliations:
- Institute of immunology
- Issue: Vol 12, No 2 (2015)
- Pages: 68-74
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2015
- URL: https://rusalljournal.ru/raj/article/view/470
- DOI: https://doi.org/10.36691/RJA470
- ID: 470
Cite item
Abstract
In the article the question of asthma control, the main reasons for its absence. The variant replacement used inhaled corticosteroids while maintaining equipotent doses as a way to achieve asthma control without increasing the pharmacologic stress.
Full Text
About the authors
O M Kurbacheva
Institute of immunology
Email: kurbacheva@gmail.com
K S Pavlova
Institute of immunology
References
- Global Initiative for Asthma (GINA Report). Global Strategy for Asthma Management and Prevention. Update 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014.pdf.
- Аллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.
- Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 3-е изд., испр. и доп. М., «Атмосфера». 2008, 108 с.
- Назарова Е.В., Курбачева О.М., Ильина Н.И. Алгоритм оценки контроля бронхиальной астмы. Рос. Аллергол. Журн. 2011, № 2, с. 18-23.
- Juniper E.F., Bousquet J., Abetz L., Bateman E.D. GOAL Committee. Identifying ‘well-controlled’ and ‘not wellcontrolled’ asthma using the Asthma Control Questionnaire. Respir. Med. 2006, v. 100, p. 616-621.
- Zhou J., Liu D.F., Liu C. et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy. 2008, v. 63, p. 1177-1185.
- Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус принт». 1998, 252 с.
- Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. 1997, v. 91, p. 22-28.
- Цой А.Н. Что определяет эффективность и безопасность применения ингаляционных ГКС в поддержании контроля над симптомами астмы. Справочник поликлинического врача. 2010, № 2, с. 37-43.
- Winkler J., Hochhaus G., Derendorf H. How the lung handles drugs. Pharmacocinetics and pharmacodinamics of inchaled corticosteroids. Proc. Am. Thorac. Soc. 2004, v. 1, p. 356-363.
- Rossi G.A., Cerasoli F., Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulmonary Pharmacology & Therapeutics. 2007, v. 20, p. 23-35.
- Maspero J.F., Nolte H., Chérrez-Ojeda I. P04139 Study Group. Long-term safety of mometasone furoate / formoterol combination for treatment of patients with persistent asthma. J. Asthma. 2010, v. 47, p. 1106-1115.
- Nathan R.A., Nolte H., Pearlman D.S. P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010, v. 31, p. 269-279.
- Weinstein S.F., Corren J., Murphy K. et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010, v. 31, p. 280-289.
- Corren J., Berkowitz R., Murray J.J., Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int. J. Clin. Pract. 2003, v. 57, p. 567-72.
- Nathan R.A., Nayak A.S., Graft D.F. et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann. Allergy Asthma Immunol. 2001, v. 86, p. 203-210.